Literature DB >> 7188679

Toxicity of cis-diamminedichloroplatinum II given in a two-hour outpatient regimen of diuresis and hydration.

S E Vogl, T Zaravinos, B H Kaplan.   

Abstract

A two-hour program of hydration with 2 liters of 0.45% saline-5% dextrose and diuresis with furosemide and mannitol was employed to administer cis-diamminedichloroplatinum(II) on an outpatient basis; 760 courses were administered to 158 patients. The dose was 50 mg/M2 every three to four weeks, and was given in combination with other anti-neoplastic agents in all but two patients. Only eight patients (5.13%) ever became azotemic. Of these, only three ever had serum creatinine determinations greater than 2 mg/dI, and azotemia was reversible in two months in all but one. Risk of azotemia did not increase with increasing cumulative dose. There were two anaphylactoid reactions, one sudden death, and two cases of hearing loss. Nausea and vomiting were universal, and often severe. This program of hydration and diuresis allows convenient outpatient administration of this drug with minor risk of mild nephrotoxicity.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7188679     DOI: 10.1002/1097-0142(19800101)45:1<11::aid-cncr2820450104>3.0.co;2-e

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer.

Authors:  P De Besi; B Busnardo; S Toso; M E Girelli; D Nacamulli; N Simioni; D Casara; P Zorat; M V Fiorentino
Journal:  J Endocrinol Invest       Date:  1991-06       Impact factor: 4.256

Review 2.  Guidelines for treatment of renal injury during cancer chemotherapy 2016.

Authors:  Shigeo Horie; Mototsugu Oya; Masaomi Nangaku; Yoshinari Yasuda; Yasuhiro Komatsu; Motoko Yanagita; Yuko Kitagawa; Hiroyuki Kuwano; Hiroyuki Nishiyama; Chikashi Ishioka; Hiromasa Takaishi; Hideki Shimodaira; Akira Mogi; Yuichi Ando; Koji Matsumoto; Daisuke Kadowaki; Satoru Muto
Journal:  Clin Exp Nephrol       Date:  2018-02       Impact factor: 2.801

3.  Intolerance to cisplatin--a case report.

Authors:  G E Umbach; H von Matthiessen; G Wirth; G Goerz
Journal:  Arch Gynecol       Date:  1985

4.  Factors affecting human autopsy kidney-cortex and kidney-medulla platinum concentrations after cisplatin administration.

Authors:  D J Stewart; C Dulberg; J M Molepo; N Z Mikhael; V A Montpetit; M D Redmond; R Goel
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Follow-up study of enzymuria and beta 2 microglobulinuria during cis-platinum treatment.

Authors:  A S Tirelli; N Colombo; G Cavanna; C Mangioni; B M Assael
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

6.  Improved control of cisplatin-induced emesis with a metoclopramide-dexamethasone combination.

Authors:  F Cognetti; P Pinnaro; P Carlini; C Caporali; E M Ruggeri; C F Pollera
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

7.  Oral levonantradol in the control of cancer chemotherapy-induced emesis.

Authors:  J Welsh; F Stuart; G Sangster; R Milstead; S Kaye; H Cash; D Charlton; K Calman
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

8.  A randomized trial comparing alizapride alone or with dexamethasone vs a metoclopramide-dexamethasone combination for emesis induced by moderate-dose cisplatin.

Authors:  C F Pollera; M Nardi; P Marolla; P Carlini
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 9.  Cisplatin overdose: toxicities and management.

Authors:  Roger Y Tsang; Turki Al-Fayea; Heather-Jane Au
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.